Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Applied Therapeutics, Inc. Director's Dealing 2021

Jan 9, 2021

34263_dirs_2021-01-08_bfb1b656-1248-4a96-bfa8-6b841392c2b9.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Applied Therapeutics Inc. (APLT)
CIK: 0001697532
Period of Report: 2021-01-06

Reporting Person: Perfetti Riccardo (Chief Medical Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-01-06 Common Stock M 7765 $1.44 Acquired 7765 Direct
2021-01-06 Common Stock S 165 $22.17 Disposed 7600 Direct
2021-01-06 Common Stock S 7600 $23.50 Disposed 0 Direct
2021-01-07 Common Stock M 765 $1.44 Acquired 765 Direct
2021-01-07 Common Stock S 765 $21.88 Disposed 0 Direct
2021-01-08 Common Stock M 7985 $1.44 Acquired 7985 Direct
2021-01-08 Common Stock S 300 $21.92 Disposed 7685 Direct
2021-01-08 Common Stock S 7685 $23.18 Disposed 0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-01-06 Stock Option (Right to Buy) $1.44 M 7765 Disposed 2028-12-16 Common Stock (7765) Direct
2021-01-07 Stock Option (Right to Buy $1.44 M 765 Disposed 2028-12-16 Common Stock (765) Direct
2021-01-08 Stock Option (Right to Buy $1.44 M 7985 Disposed 2028-12-16 Common Stock (7985) Direct

Footnotes

F1: Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised automatically pursuant to the reporting person's written trading plan previously entered into on September 16, 2020, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2: Automatic sales made pursuant to the reporting person's pre-existing written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3: Weighted average price. These shares were sold in multiple transactions at prices ranging from $21.9700 to $22.3000 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F4: Weighted average price. These shares were sold in multiple transactions at prices ranging from $23.0000 to $23.8800 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F5: Weighted average price. These shares were sold in multiple transactions at prices ranging from $21.5000 to $22.1600 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F6: Weighted average price. These shares were sold in multiple transactions at prices ranging from $21.4000 to $22.2100 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F7: Weighted average price. These shares were sold in multiple transactions at prices ranging from $22.8700 to $23.4150 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F8: Thirty-three percent (33%) of the shares subject to the option vested on August 27, 2018, and one twenty-fourth (1/24th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.